Injections into the vitreous in the eye, including those with OZURDEX ®, are associated with serious eye infection (endophthalmitis), eye inflammation, increased eye pressure, and retinal detachments.

Injections into the vitreous in the eye, including those with OZURDEX ®, are associated with serious eye infection (endophthalmitis), eye inflammation, increased eye pressure, and retinal detachments.

Injections into the vitreous in the eye, including those with OZURDEX ®, are associated with serious eye infection (endophthalmitis), eye inflammation, increased eye pressure, and retinal detachments.

OZURDEX ® is a corticosteroid indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).

OZURDEX ® is a corticosteroid indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).

Injections into the vitreous in the eye, including those with OZURDEX®, are associated with serious eye infection (endophthalmitis), eye inflammation, increased eye pressure, and retinal detachments.

OZURDEX® (dexamethasone intravitreal implant) resources for practices and patients. Please see Important Safety Information and Prescribing Information.

OZURDEX ® is a corticosteroid indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).

OZURDEX ® is a corticosteroid indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).

Injections into the vitreous in the eye, including those with OZURDEX ®, are associated with serious eye infection (endophthalmitis), eye inflammation, increased eye pressure, and retinal detachments.